volume 61 issue 24 pages 10996-11020

From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles

Publication typeJournal Article
Publication date2018-07-19
scimago Q1
wos Q1
SJR1.801
CiteScore11.5
Impact factor6.8
ISSN00222623, 15204804
Drug Discovery
Molecular Medicine
Abstract
Oxygen heterocycles are the second most common type of heterocycles that appear as structural components of U.S. Food and Drug Administration (FDA) approved pharmaceuticals. Analysis of our database of drugs approved through 2017 reveals 311 distinct pharmaceuticals containing at least one oxygen heterocycle. Most prevalent among these are pyranoses, with furanoses, macrolactones, morpholines, and dioxolanes rounding off the top five. The main body of this Perspective is organized according to ring size, commencing with three- and four-membered rings and ending with macrocycles, polymers, and unusual oxygen-containing heterocycles. For each section, all oxygen heterocycle-containing drugs are presented along with a brief discussion about structural and drug application patterns.
Found 
Found 

Top-30

Journals

5
10
15
20
25
Organic Letters
22 publications, 6.75%
Journal of Organic Chemistry
21 publications, 6.44%
Angewandte Chemie - International Edition
18 publications, 5.52%
Angewandte Chemie
18 publications, 5.52%
Journal of the American Chemical Society
12 publications, 3.68%
Advanced Synthesis and Catalysis
12 publications, 3.68%
Organic Chemistry Frontiers
12 publications, 3.68%
Chemical Science
11 publications, 3.37%
Journal of Medicinal Chemistry
10 publications, 3.07%
Organic and Biomolecular Chemistry
9 publications, 2.76%
European Journal of Organic Chemistry
9 publications, 2.76%
Chemical Communications
9 publications, 2.76%
RSC Advances
7 publications, 2.15%
Tetrahedron
6 publications, 1.84%
ACS Catalysis
6 publications, 1.84%
Molecules
5 publications, 1.53%
Journal of Molecular Structure
5 publications, 1.53%
Green Chemistry
5 publications, 1.53%
Chemistry - A European Journal
5 publications, 1.53%
Asian Journal of Organic Chemistry
4 publications, 1.23%
Bioorganic Chemistry
4 publications, 1.23%
ACS Omega
4 publications, 1.23%
Synthesis
4 publications, 1.23%
Catalysts
3 publications, 0.92%
Bioorganic and Medicinal Chemistry
3 publications, 0.92%
Accounts of Chemical Research
3 publications, 0.92%
Synthetic Communications
3 publications, 0.92%
Nature Communications
3 publications, 0.92%
Results in Chemistry
2 publications, 0.61%
5
10
15
20
25

Publishers

10
20
30
40
50
60
70
80
90
American Chemical Society (ACS)
85 publications, 26.07%
Wiley
82 publications, 25.15%
Royal Society of Chemistry (RSC)
54 publications, 16.56%
Elsevier
45 publications, 13.8%
Springer Nature
16 publications, 4.91%
MDPI
10 publications, 3.07%
Taylor & Francis
9 publications, 2.76%
Georg Thieme Verlag KG
6 publications, 1.84%
Bentham Science Publishers Ltd.
6 publications, 1.84%
Beilstein-Institut
2 publications, 0.61%
American Society for Pharmacology and Experimental Therapeutics
1 publication, 0.31%
Oxford University Press
1 publication, 0.31%
Shanghai Institute of Organic Chemistry
1 publication, 0.31%
Pleiades Publishing
1 publication, 0.31%
Institute of Electrical and Electronics Engineers (IEEE)
1 publication, 0.31%
Public Library of Science (PLoS)
1 publication, 0.31%
American Association for the Advancement of Science (AAAS)
1 publication, 0.31%
Frontiers Media S.A.
1 publication, 0.31%
OOO Zhurnal "Mendeleevskie Soobshcheniya"
1 publication, 0.31%
10
20
30
40
50
60
70
80
90
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
328
Share
Cite this
GOST |
Cite this
GOST Copy
Delost M. D. et al. From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles // Journal of Medicinal Chemistry. 2018. Vol. 61. No. 24. pp. 10996-11020.
GOST all authors (up to 50) Copy
Delost M. D., Smith D. T., Anderson B. J., Njardarson J. T. From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles // Journal of Medicinal Chemistry. 2018. Vol. 61. No. 24. pp. 10996-11020.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1021/acs.jmedchem.8b00876
UR - https://doi.org/10.1021/acs.jmedchem.8b00876
TI - From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles
T2 - Journal of Medicinal Chemistry
AU - Delost, Michael D
AU - Smith, David T
AU - Anderson, Benton J
AU - Njardarson, J. T.
PY - 2018
DA - 2018/07/19
PB - American Chemical Society (ACS)
SP - 10996-11020
IS - 24
VL - 61
PMID - 30024747
SN - 0022-2623
SN - 1520-4804
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2018_Delost,
author = {Michael D Delost and David T Smith and Benton J Anderson and J. T. Njardarson},
title = {From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles},
journal = {Journal of Medicinal Chemistry},
year = {2018},
volume = {61},
publisher = {American Chemical Society (ACS)},
month = {jul},
url = {https://doi.org/10.1021/acs.jmedchem.8b00876},
number = {24},
pages = {10996--11020},
doi = {10.1021/acs.jmedchem.8b00876}
}
MLA
Cite this
MLA Copy
Delost, Michael D., et al. “From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles.” Journal of Medicinal Chemistry, vol. 61, no. 24, Jul. 2018, pp. 10996-11020. https://doi.org/10.1021/acs.jmedchem.8b00876.
Profiles